Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PLD2 | O14939 | 1/20 | 0.31 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426618 | 0.92 | UTS2R (0.45) | UTS2R | |
| SCHEMBL4438280 | 0.78 | UTS2R (0.42) | UTS2RCYP2C19 | |
| SCHEMBL4440269 | 0.78 | UTS2R (0.41) | UTS2RCYP2C19PLD2PLD1 | |
| SCHEMBL4881578 | 0.74 | UTS2R (0.60) | UTS2R | |
| SCHEMBL4884060 | 0.73 | UTS2R (0.46) | UTS2R | |
| SCHEMBL4439938 | 0.73 | UTS2R (0.43) | UTS2R | |
| SCHEMBL4431353 | 0.72 | MAPT (0.40) | UTS2R | |
| SCHEMBL4430255 | 0.72 | UTS2R (0.38) | UTS2R | |
| SCHEMBL4440091 | 0.72 | UTS2R (0.45) | UTS2R | |
| SCHEMBL4430180 | 0.72 | UTS2R (0.43) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | UTS2R 1/4885CYP2C19 4421/4885PLD2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.